Publication Date: 2021/07/28
Abstract: Glaucoma is the most prevalent neurodegenerative disorder of the eye. It is often called “silent thief of vision” as the symptoms gradually develop and is identified in the later stage of disease that leads to serious irreparable vision impairment. Current trends in the treatment primarily aims at reducing the IOP through pharmacological agents, laser therapy and surgery. Less invasive topical regimens are the most preferred treatment option opted by the patients. Although, these topical therapies are highly preferred and efficacious the downsides of this traditional method involves poor patient compliance and low adherence to prescription. Novel ocular drug delivery platforms offer targeted drug delivery in addition to good therapeutic potential and is independent of patient administration. The role of the innovative drug delivery systems available should be emphasized. This review aims to highlight the recent trends and challenges in ocular drug delivery systems that are commercially available today and to be approved in the future overcoming the limitations of the customary traditional method. Multiple research works have shown sustained drug delivery system that are non-invasive, provide better patient compliance and can benefit the patient and physician alike.
Keywords: Glaucoma, Targeted Drug Delivery, Sustained Release, Compliance, Adherence
DOI: No DOI Available
PDF: https://ijirst.demo4.arinfotech.co/assets/upload/files/IJISRT21JUL280.pdf
REFERENCES